FDA announces reforms of drug review process.

FDA announces plans to regulate LDTs.

FDA reforms. Private doubts, public support.

Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.

2014 FDA drug approvals.



Niche markets and evidence assessment in transition: a critical review of proposed drug reforms.

Drug delay and the FDA.

Automatic extraction of drug indications from FDA drug labels.

Drug development and FDA approval, 1938-2013.

FDA vs. free speech over drug promotions.

FDA defends generic drug labeling plan.

FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.

SKB announces UK redundancies and realignment.

EFRACom announces food security inquiry.

Indirect costs. OMB announces cap.

User fees to hasten FDA review.

FDA regulation of OTC oral health care drug products.

Primary care physicians' use of FDA-approved prescription drug labels.

Regulation of O-T-C drug advertising: the FDA "prescription".

FDA declines approval of testosterone drug for third time.

Innovations announces a new affiliation.

Erato announces new research targets.

New FDA breakthrough-drug category--implications for patients.

FDA announces plans to regulate LDTs.

FDA reforms. Private doubts, public support.

Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.

2014 FDA drug approvals.

2015 FDA drug approvals.

2013 FDA drug approvals.

Niche markets and evidence assessment in transition: a critical review of proposed drug reforms.

Drug delay and the FDA.

Automatic extraction of drug indications from FDA drug labels.

Drug development and FDA approval, 1938-2013.

FDA vs. free speech over drug promotions.

FDA defends generic drug labeling plan.

FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.

SKB announces UK redundancies and realignment.

EFRACom announces food security inquiry.

Indirect costs. OMB announces cap.

User fees to hasten FDA review.

FDA regulation of OTC oral health care drug products.

Primary care physicians' use of FDA-approved prescription drug labels.

Regulation of O-T-C drug advertising: the FDA "prescription".

FDA declines approval of testosterone drug for third time.

Innovations announces a new affiliation.

Erato announces new research targets.

New FDA breakthrough-drug category--implications for patients.